Due a network of dysfunctional blood vessels, many parts of tumours have poor delivery of oxygen and nutrients, leading to a tumour microenvironment (TME) that is hypoxic, low in glucose and acidic. These tumour-specific conditions have been targeted by various therapeutic agents in development, such as hypoxia-activated pro-drugs and proton pump inhibitors. Although a number of genes are known to play a role in tolerance to these TME stressors, the relative importance of these is unknown, while there could be additional genes that contribute that have yet to be identified.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.